Literature DB >> 7909948

Dopamine D2 receptor density estimates in schizophrenia: a positron emission tomography study with 11C-N-methylspiperone.

L E Tune1, D F Wong, G Pearlson, M Strauss, T Young, E K Shaya, R F Dannals, A A Wilson, H T Ravert, J Sapp.   

Abstract

Positron emission tomography (PET) with 11C-N-methylspiperone as the radioligand was carried out in 25 chronic schizophrenic patients to determine dopamine D2 receptor density estimates in the corpus striatum. The sample included 18 neuroleptic-naive and 7 neuroleptic-free patients. Dopamine D2 receptor density estimates (Bmax) were obtained using a two-scan/four-compartment model. The Bmax estimates for the entire group (33.39 +/- 3.43 pmole/g) were significantly elevated when compared with estimates for the control group (Bmax = 15.63 +/- 2.38). The Bmax values for the entire group of schizophrenic patients showed a significant decline as a function of age. The Bmax values were significantly related to duration of illness (y = 13.2 + 10.3795x - 0.7931x2; r = 0.48). Thirteen patients and seven control subjects were added to our original publication sample (Wong et al., 1986c). The patients' Bmax values, when adjusted for age and sex effects, were significantly different compared with those of control subjects. Clinical data from the entire group were compared with published data from other research groups that have estimated dopamine D2 receptor density using different radioligands and different methods of data analysis. Comparisons of the clinical characteristics of the published studies show significant differences in patient populations, suggesting that discrepancies among published studies may reflect, in part, heterogeneity among groups of schizophrenic patients. The D2 receptor abnormality described in this study may be a late manifestation of disease, and the implications of this observation are discussed.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7909948     DOI: 10.1016/0165-1781(93)90063-m

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  12 in total

Review 1.  Traditional receptor theory and its application to neuroreceptor measurements in functional imaging.

Authors:  R W Kerwin; L S Pilowsky
Journal:  Eur J Nucl Med       Date:  1995-07

Review 2.  Dysfunctional brain networks and genetic risk for schizophrenia: specific neurotransmitter systems.

Authors:  Jussi Hirvonen; Jarmo Hietala
Journal:  CNS Neurosci Ther       Date:  2010-12-28       Impact factor: 5.243

3.  18F-fallypride binding potential in patients with schizophrenia compared to healthy controls.

Authors:  Douglas S Lehrer; Bradley T Christian; Cemil Kirbas; Meicheng Chiang; Shawn Sidhu; Holly Short; Binquan Wang; Bingzhi Shi; King-Wai Chu; Brian Merrill; Monte S Buchsbaum
Journal:  Schizophr Res       Date:  2010-07-23       Impact factor: 4.939

4.  Dopamine D2 and D3 binding in people at clinical high risk for schizophrenia, antipsychotic-naive patients and healthy controls while performing a cognitive task.

Authors:  Ivonne Suridjan; Pablo Rusjan; Jean Addington; Alan A Wilson; Sylvain Houle; Romina Mizrahi
Journal:  J Psychiatry Neurosci       Date:  2013-03       Impact factor: 6.186

5.  Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method.

Authors:  A Breier; T P Su; R Saunders; R E Carson; B S Kolachana; A de Bartolomeis; D R Weinberger; N Weisenfeld; A K Malhotra; W C Eckelman; D Pickar
Journal:  Proc Natl Acad Sci U S A       Date:  1997-03-18       Impact factor: 11.205

Review 6.  Motor system dysfunction in the schizophrenia diathesis: Neural systems to neurotransmitters.

Authors:  R Abboud; C Noronha; V A Diwadkar
Journal:  Eur Psychiatry       Date:  2017-04-25       Impact factor: 5.361

Review 7.  Imaging-based neurochemistry in schizophrenia: a systematic review and implications for dysfunctional long-term potentiation.

Authors:  Bahar Salavati; Tarek K Rajji; Rae Price; Yinming Sun; Ariel Graff-Guerrero; Zafiris J Daskalakis
Journal:  Schizophr Bull       Date:  2014-09-22       Impact factor: 9.306

8.  Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects.

Authors:  M Laruelle; A Abi-Dargham; C H van Dyck; R Gil; C D D'Souza; J Erdos; E McCance; W Rosenblatt; C Fingado; S S Zoghbi; R M Baldwin; J P Seibyl; J H Krystal; D S Charney; R B Innis
Journal:  Proc Natl Acad Sci U S A       Date:  1996-08-20       Impact factor: 11.205

9.  Striatal dopamine D2 receptor density in neuroleptic-naive and in neuroleptic-free schizophrenic patients: an 123I-IBZM-SPECT study.

Authors:  Francisco Lomeña; Ana M Catafau; Eduard Parellada; Miquel Bernardo; Mireia Font; Fernando Gutiérrez; Javier Pavía
Journal:  Psychopharmacology (Berl)       Date:  2003-11-18       Impact factor: 4.530

10.  The role of striatal dopamine D2/3 receptors in cognitive performance in drug-free patients with schizophrenia.

Authors:  Tanja Veselinović; Ingo Vernaleken; Hildegard Janouschek; Paul Cumming; Michael Paulzen; Felix M Mottaghy; Gerhard Gründer
Journal:  Psychopharmacology (Berl)       Date:  2018-05-01       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.